EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)

An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1

Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, John W Day, Jeffrey M Statland, Payam Soltanzadeh, Sankarasubramoney H Subramony, Charles A Thornton, W David Arnold, Matthew Wicklund, Miriam L Freimer, Kate Eichinger und 8 weitere

New England Journal of Medicine · 19.02.2026 · 394 (8) · 763-772

DOI: 10.1056/nejmoa2407326 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.02.2026. Verfasst von Nicholas E Johnson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoconjugates, Myotonic Dystrophy, Myotonin-Protein Kinase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Avidity Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalImmunoconjugatesMyotonic DystrophyMyotonin-Protein KinaseOligonucleotidesReceptors, TransferrinAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodRNA, MessengerGain of Function MutationAlternative SplicingBiopsyTreatment Outcome

Substanzen

Antibodies, MonoclonalDMPK protein, humanImmunoconjugatesMyotonin-Protein KinaseOligonucleotidesReceptors, TransferrinRNA, Messenger

Autor:innen und Institutionen

  • Virginia Commonwealth University, Richmond.
  • Avidity Biosciences, San Diego, CA.
  • University of Rochester Medical Center, Rochester, NY.
  • Stanford University Medical Center, Palo Alto, CA.
  • University of Kansas Medical Center, Kansas City.
  • University of California, Los Angeles, Los Angeles.

Förderung

  • Avidity Biosciences

Zitieren

APA

Johnson, N. E., Tai, L. J., Hamel, J. I., Day, J. W., Statland, J. M., Soltanzadeh, P., Subramony, S. H., Thornton, C. A., Arnold, W. D., Wicklund, M., Freimer, M. L., Eichinger, K., Dekdebrun, J., Chen, C. Y., Goel, V., McEvoy, B., Zhu, Y., Hughes, S. G., Ackermann, E. J., & Levin, A. A. (2026). An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. New England Journal of Medicine, 394(8), 763-772. https://doi.org/10.1056/nejmoa2407326

Vancouver

Johnson NE, Tai LJ, Hamel JI, Day JW, Statland JM, Soltanzadeh P, et al. An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. New England Journal of Medicine. 2026;394(8):763-772. doi:10.1056/nejmoa2407326

BibTeX
@article{Johnson2026,
  author = {Johnson, Nicholas E and Tai, Li-Jung and Hamel, Johanna I and Day, John W and Statland, Jeffrey M and Soltanzadeh, Payam and Subramony, Sankarasubramoney H and Thornton, Charles A and Arnold, W David and Wicklund, Matthew and Freimer, Miriam L and Eichinger, Kate and Dekdebrun, Jeanne and Chen, Chao-Yin and Goel, Varun and McEvoy, Bradley and Zhu, Yiming and Hughes, Steven G and Ackermann, Elizabeth J and Levin, Arthur A},
  title = {An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {8},
  pages = {763--772},
  doi = {10.1056/nejmoa2407326}
}
Kostenlos starten →